Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET
Company Participants
Juan Sanchez - VP, Corporate Communications & IR
Sharon Mates - Co-Founder, Chairman, CEO & President
Mark Neumann - EVP & Chief Commercial Officer
Lawrence Hineline - SVP, Finance, CFO, Treasurer & Assistant Secretary
Suresh Durgam - EVP & Chief Medical Officer
Conference Call Participants
Andrew Tsai - Jefferies
Brian Abrahams - RBC Capital Markets
Michael DiFiore - Evercore ISI
Ami Fadia - Needham & Company
Ashwani Verma - UBS
David Amsellem - Piper Sandler & Co.
Marc Goodman - SVB Securities
Graig Suvannavejh - Mizuho Securities
Charles Duncan - Cantor Fitzgerald
Operator
Good morning, ladies and gentlemen, and welcome to intracellular Therapies Third Quarter Earnings Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions]. As a reminder, today's conference call is being recorded. I'd now like to turn the conference over to Dr. Juan Sanchez, Vice President, Corporate Communications and Investor Relations.
Juan Sanchez
Good morning, and thank you all for joining us on the call today. Our earnings press release provides a corporate update and details of the company's financial results for the third quarter ended September 30th, 2022. This press release class award this morning and is available on our website at intracellulartherapies.com. Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Mark Neumann, Executive Vice President and Chief Commercial Officer; Dr. Suresh Dargan, Executive Vice President and Chief Medical Officer; and Larry Hineline, Senior Vice President and Chief Financial Officer. As a reminder, during today's call, we will be making certain forward-looking statements.
These statements may include statements regarding, among other things, the efficacy, safety and intended use of the company's product development candidates, our clinical and nonclinical plans, our plans to present and report additional data, the anticipated conduct and results of ongoing and future clinical trials, plans regarding regulatory filings, future research and development, our plans and expectations regarding the commercialization of CAPLYTA; potential impact of COVID-19 pandemic on our business; and possible uses of existing cash and investment resources. These forward-looking statements are based on current information, assumptions and expectations which are subject to change and involve a number of risks and uncertainties that might cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are discussed in our [indiscernible] filings made with the Securities and Exchange Commission, including our quarterly and annual reports. You're cautioned not to place undue reliance on these forward-looking statements, and the company disclaims any obligation to base such statements. I will now turn the call over to Sharon.